sis. His platelet count gradually increased and normalized after cessation of heparin.
Five years after that HIT episode, he developed right lower leg ischemic necrosis and was again admitted to hospital. Laboratory tests showed his serum creatinine level had elevated to 1.6 mg/dl and creatinine clearance had decreased to 43 ml/min. Arteriography revealed complete occlusion of both common iliac arteries, and consequently he underwent axillobifemoral bypass surgery using an expanded polytetrafluoroethylene graft. In the operating room, 30 min prior to the arterial clamp, continuous intravenous infusion of argatroban was started. An activated clotting time of 150 s was achieved using 2.7 g· kg -1 · min -1 of argatroban. He received 10 mg in total of argatroban in 1 h, before and during the arterial clamp. The bypass surgery was successfully performed in 3 h without any thromboembolic or bleeding complications. He was started on a permanent warfarin regimen, beginning after surgery. The postoperative course was uneventful and his ischemic symptoms improved.
Discussion
HIT is a rare but lethal syndrome caused by antibodies against complexes of platelet factor 4 and heparin (HIT antibodies). 1 Patients with HIT have profound thrombocytopenia, sometimes associated with thrombosis. Thrombotic events are most frequently venous, but arterial thrombosis leading to myocardial infarction and ischemic limb damage requiring amputation also occur. The mortality rate can reach 20-30%. 1 No consensus currently exists on the best alternative anticoagulant for patients with a history of HIT who must undergo cardiac or vascular surgery. Recent reports recommend the use of recombinant hirudin (Lepirudin), 3 which is a direct thrombin inhibitor; however, this agent is not available in Japan and furthermore, patients with renal dysfunction (creatinine >1.5 mg/dl) have a greater risk of postoperative bleeding. 4 Another report favors danaparoid (Orgaran), but it also carries the risk of life-threatening hemorrhage because of its variable elimination half-life. 5 In addition, the 
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activated clotting time does not correlate with the plasma concentration of Orgaran. 5 Low molecular weight heparin has been used but was abandoned because of cross-reactivity with HIT antibodies. 6 More recently, Potzsch et al reported that antibody-negative patients with a history of HIT undergoing cardiopulmonary bypass have been safely treated with heparin. 7 Certainly, in some cases, HIT antibodies become undetectable a few months after the cessation of heparin therapy; 1 however, the assay for the antibodies against complexes of platelet factor 4 and heparin is not widely available in Japan. Furthermore, the number of patients in the Potzsch et al report was small, 7 so we believe the use of heparin in such patients should be restricted because the risk of recurrent HIT is unknown. Argatroban, which is also a direct thrombin inhibitor, may be a good alternative intraoperative anticoagulant for patients with HIT. It has been safely used as an anticoagulant in a variety of cardiovascular operations, 2 and because it does not resemble heparin, there is no cross-reactivity with HIT antibodies. 8 Pharmacokinetic evaluation suggests that argatroban is easy to monitor and control, with little potential for overdosing or underdosing, regardless of age or renal function. 9 The efficacy of argatroban is easily monitored by measuring activated clotting times, as was done in the present case. The dosages of argatroban required to achieve a variety of target activated clotting times have been documented 2 and more importantly, because argatroban has little potential for overdosing regardless of renal function, it can be safely used even in patients with renal dysfunction. In addition, it has been recently reported that argatroban anticoagulation can be used as treatment during an acute HIT episode. 10 In that study, argatroban reduced new thromboses and achieved a more rapid rise in platelet counts in patients who were developing HIT, without increasing the bleeding risk. These findings support the safety of argatroban for HIT patients and indicate its advantages over other anticoagulants.
In summary, when patients with a history of HIT undergo peripheral vascular surgery, argatroban, at a dose determined by titration of activated clotting times, is a viable anticoagulation substitute for heparin.
